A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma

Clinical Therapeutics

Volumn 28, Issue 6, 2006, Pages 906-920

  Hansel, Trevor T ^a   Benezet, Olivier ^b   Kafé, Henri ^c   Ponitz, Hans Hermann ^d   Cheung, David ^e   Engelstätter, Renate ^f   Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b Valmedica   (France)

^c Cabinet de Pneumologie   (France)

^d Lungenpraxis   (Germany)

^e Vlietland Hospital   (Netherlands)

^f ALTANA PHARMA AG   (Germany)

Author keywords

asthma; budesonide; ciclesonide; cortisol; inhaled corticosteroid; pulmonary function

Indexed keywords

BUDESONIDE; CICLESONIDE; CORTICOSTEROID; CREATININE; HYDROCORTISONE; PLACEBO; SALBUTAMOL; TERBUTALINE;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; ASTHMA; BIOLOGICAL MONITORING; BODY WEIGHT; BRONCHITIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE URINE LEVEL; DEMOGRAPHY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EUROPE; FEMALE; FLU LIKE SYNDROME; FORCED EXPIRATORY VOLUME; GENERAL CONDITION IMPROVEMENT; HEMODYNAMIC MONITORING; HORMONE INHIBITION; HOSPITAL LABORATORY; HUMAN; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NIGHT; PEAK EXPIRATORY FLOW; PHYSICAL EXAMINATION; POPULATION; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RHINITIS; SCHOOL CHILD; SCORING SYSTEM; SEX; SYMPTOM; UPPER RESPIRATORY TRACT INFECTION; URINARY EXCRETION; VITAL SIGN;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ASTHMA; BUDESONIDE; CHILD; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; PREGNENEDIONES; RESPIRATORY FUNCTION TESTS;

EID: 33745959255     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.06.014     Document Type: Article

References (37)

1. Pocket Guide for Asthma Management and Prevention in Children (2004), Global Initiative for Asthma, Bethesda, Md
2. Available at:. Williams S.G., Schmidt D.K., Redd S.C., and Storms W. Key clinical activities for quality asthma care. Recommendations of the National Asthma Education and Prevention Program. Accessed (May 26, 2005). http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5206al.htm
3. Lin H., and Casale T.B. Treatment of allergic asthma. Am J Med 113 Suppl 9A (2002) 8S-16S
4. Bhalay G., and Sandham D.A. Recent advances in corticosteroids for the treatment of asthma. Curr Opin Investig Drugs 3 (2002) 1149-1156
5. Adcock I.M., Gilbey T., Gelder C.M., et al. Glucocorticoid receptor localization in normal and asthmatic lung. Am J Respir Crit Care Med 154 (1996) 771-782
6. Ciclesonide B.Y. 9010, ciclesonide-DPI, ciclesonide-MDI, EL 876. Drugs R D 3 (2002) 407-410
7. Mealy N.E., Bayes M., and Castaner J. Ciclesonide. Drugs Future 26 (2001) 1033-1039
8. (Suppl). Belvisi M., Bundschuh D., Stoeck M., et al. Ciclesonide, a novel "on site activated" inhaled corticosteroid with potent anti-inflammatory actions in the airways. Abstract 59. J Allerg Clin Immunol 109 (2002) S37
9. Dietzel K., Engelstätter R., and Keller A. Ciclesonide: An on-siteactivated steroid. Prog Respir Res 31 (2001) 91-93
10. (Suppl). Rohatagi S., Derendorf H., Zech K., et al. PK/PD of inhaled corticosteroids: The risk/benefit of inhaled ciclesonide. Abstract 598. J Allergy Clin Immunol 111 (2003) S218
11. Nave R., Meyer W., Fuhst R., and Zech K. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther 18 (2005) 390-396
12. Rohatagi S., Luo Y., Shen L., et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther 12 (2005) 201-209
13. Rohatagi S., Arya V., Zech K., et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol 43 (2003) 365-378
14. Newman S., Salmon A., Nave R., and Drollman A. High lung deposition of 99mTc-labelled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 100 (2006) 375-384
15. Taylor D.A., Jensen M.W., Kanabar V., et al. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5′-monophosphate in asthmatic patients. Am J Respir Crit Care Med 160 (1999) 237-243
16. Postma D.S., Sevette C., Martinat Y., et al. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J 17 (2001) 1083-1088
17. Weinbrenner A., Huneke D., Zschiesche M., et al. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab 87 (2002) 2160-2163
18. Abstract G75. O'Connor B., Sips P., Engelstätter R., et al. Management of moderate to severe bronchial asthma by ciclesonide: A 12-week trial. Am J Respir Crit Care Med 165 (2002) A767
19. Langdon C.G., Adler M., Mehra S., et al. Once-daily ciclesonide 80 or 320 μg for 12 weeks is safe and effective in patients with persistent asthma. Respir Med 99 (2005) 1275-1285
20. Derom E., Van De Velde V., Marissens S., et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′monophosphate in asthmatic patients. Pulm Pharmacol Ther 18 (2005) 328-336
21. Larsen B.B., Nielsen L.P., Engelstatter R., et al. Effect of ciclesonide on allergen challenge in subjects with bronchial asthma. Allergy 58 (2003) 207-212
22. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis. 136 (1987) 225-244
23. Ebbutt A.F., and Frith L. Practical issues in equivalence trials. Stat Med 17 (1998) 1691-1701
24. Kanniess F., Richter K., Bohme S., et al. Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm Pharmacol Ther 14 (2001) 141-147
25. Chuchalin A.G., Kremer H.J., Metzenauer P., et al. Clinical equivalence trial on budesonide delivered either by the Novolizer multidose dry powder inhaler or the Turbuhaler in asthmatic patients. Respiration 69 (2002) 502-508
26. Boulet L.P. Once-daily inhaled corticosteroids for the treatment of asthma. Curr Opin Pulm Med 10 (2004) 15-21
27. Masoli M., Weatherall M., Holt S., and Beasley R. Budesonide once versus twice-daily administration: Meta analysis. Respirology 9 (2004) 528-534
28. Selroos O., Edsbacker S., and Hultquist C. Once-daily inhaled budesonide for the treatment of asthma: Clinical evidence and pharmacokinetic explanation. J Asthma 41 (2004) 771-790
29. Pulmicort Turbuhaler 200 mcg [package insert] (2001), AstraZeneca, Wilmington, Del
30. Szefler S., and Pedersen S. Role of budesonide as maintenance therapy for children with asthma. Pediatr Pulmonol 36 (2003) 13-21
31. Newman S.P. Deposition and effects of inhaled corticosteroids. Clin Pharmacokinet 42 (2003) 529-544
32. Niphadkar P., Jagannath K., Joshi J.M., et al. Comparison of the efficacy of ciclesonide 160 μg QD and budes onide 200 μg BID in adults with persistent asthma: A phase III, randomized, double-dummy, open-label study. Clin Ther 27 (2005) 1752-1763
33. Boulet L.P., Drollmann A., Magyar P., et al. Comparative efficacy of oncedaily ciclesonide and budesonide in the treatment of persistent asthma. Respir Med 100 (2006) 785-794
34. Szefler S., Rohatagi S., Williams J., et al. Ciclesonide, a novel inhaled steroid, does not affect hypothalamicpituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest 128 (2005) 1104-1114
35. Lipworth B.J., Kaliner M.A., LaForce C.F., et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 94 (2005) 465-472
36. Lipworth B.J. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta analysis. Arch Intern Med 159 (1999) 941-955
37. Kelly H.W., and Nelson H.S. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol 112 (2003) 469-478